Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox
August 29, 2022 10:45 ET
|
Chimerix, Inc.
- Initial Procurement of 319,000 Treatment Courses for $115M with Additional Procurements at BARDA’s Discretion Over 10 Years – - Emergent BioSolutions, Inc. Payment Increases to $238M Upfront...
Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update
August 08, 2022 16:01 ET
|
Chimerix, Inc.
– ONC201 Phase 3 ACTION Study Planned to Initiate This Year – –~$32M in Revenue from International TEMBEXA Agreements Recently Recognized– – U.S. Anti-Trust Clearance Obtained for Sale of TEMBEXA to...
Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory Affairs
August 08, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix to Present at Wedbush PacGrow Healthcare Conference
August 02, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients...
Chimerix to Report Second Quarter 2022 Financial Results and Provide an Operational Update on August 8, 2022
August 01, 2022 16:01 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients...
Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada
June 24, 2022 10:06 ET
|
Chimerix, Inc.
DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement
June 23, 2022 09:15 ET
|
Chimerix, Inc.
DURHAM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix to Present at Jefferies Global Healthcare Conference
June 01, 2022 16:30 ET
|
Chimerix, Inc.
DURHAM, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix to Present at H.C. Wainwright Global Investment Conference
May 17, 2022 16:15 ET
|
Chimerix, Inc.
DURHAM, N.C., May 17, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports First Quarter 2022 Financial Results and Provides Operational Update
May 16, 2022 07:00 ET
|
Chimerix, Inc.
– Receiving up to $337.5 Million plus Royalties for Sale of Worldwide Rights of TEMBEXA to Emergent BioSolutions – – Initiation of Phase 3 Randomized Study of ONC201 in H3 K27M Mutant Glioma Expected...